Literature DB >> 25342642

Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.

Jon Zugazagoitia1, Pedro Pérez-Segura, Arancha Manzano, Ignacio Blanco, Ana Vega, Ana Custodio, Alex Teulé, Laura Fachal, Beatriz Martínez, Rogelio González-Sarmiento, Juan Jesús Cruz-Hernández, Isabel Chirivella, Vicente Garcés, Pilar Garre, Atocha Romero, Trinidad Caldés, Eduardo Díaz-Rubio, Miguel de la Hoya.   

Abstract

Early-onset diagnosis is an eligibility criterion for BRCA1 and BRCA2 (BRCA) testing in sporadic breast cancer patients. Limited family structure has been proposed as a predictor of BRCA mutation status in this group of patients. An overwhelming amount of data supports a strong association between BRCA1 mutations and triple-negative breast cancer (TNBC). Here, we analyze the feasibility of using limited family structure and TNBC as predictors of BRCA mutation status in early-onset breast cancer patients attending genetic counseling units. We have conducted the study in a cohort of sporadic early-onset (≤35 years) breast cancer patients (N = 341) previously selected for BRCA genetic testing in Academic Hereditary Cancer Clinics from Spain. A retrospective review of medical records available at the time of risk assessment allowed us classifying patients according to family structure and TNBC. In addition, BRCAPRO score was calculated for all patients. Association between categorical variables was investigated using the Fisher's exact test. Binary Logistic Regression Analysis was used for multivariate analysis. Limited family structure (OR 3.61, p = 0.013) and TNBC (OR 3.14, p = 0.013) were independent predictors of BRCA mutation status. Mutation prevalence in the subgroup of patients with at least one positive predictor was 14%, whereas it dropped to 3% in non-TNBCs with adequate family history (OR 5.31, 95% CI 1.38-23.89, p = 0.006). BRCAPRO correctly discerned between limited and adequate family structures. Limited family structure and TNBC are feasible predictors of BRCA mutation status in sporadic early-onset (≤35 years) breast cancer patients attending genetic counseling units. The low prevalence of mutations observed in non-TNBCs with adequate family structure suggests that this subgroup of patients might be excluded from genetic testing.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25342642     DOI: 10.1007/s10549-014-3167-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

Review 1.  Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer.

Authors:  Nikolaos Garmpis; Christos Damaskos; Anna Garmpi; Konstantinos Nikolettos; Dimitrios Dimitroulis; Evangelos Diamantis; Paraskevi Farmaki; Alexandros Patsouras; Errika Voutyritsa; Athanasios Syllaios; Constantinos G Zografos; Efstathios A Antoniou; Nikos Nikolettos; Alkiviadis Kostakis; Konstantinos Kontzoglou; Dimitrios Schizas; Afroditi Nonni
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.

Authors:  Priyanka Sharma; Sara López-Tarruella; Jose Angel García-Saenz; Claire Ward; Carol S Connor; Henry L Gómez; Aleix Prat; Fernando Moreno; Yolanda Jerez-Gilarranz; Augusti Barnadas; Antoni C Picornell; Maria Del Monte-Millán; Milagros Gonzalez-Rivera; Tatiana Massarrah; Beatriz Pelaez-Lorenzo; María Isabel Palomero; Ricardo González Del Val; Javier Cortes; Hugo Fuentes Rivera; Denisse Bretel Morales; Iván Márquez-Rodas; Charles M Perou; Jamie L Wagner; Joshua M V Mammen; Marilee K McGinness; Jennifer R Klemp; Amanda L Amin; Carol J Fabian; Jaimie Heldstab; Andrew K Godwin; Roy A Jensen; Bruce F Kimler; Qamar J Khan; Miguel Martin
Journal:  Clin Cancer Res       Date:  2016-06-14       Impact factor: 12.531

Review 3.  Current advances in biomarkers for targeted therapy in triple-negative breast cancer.

Authors:  Brett Fleisher; Charlotte Clarke; Sihem Ait-Oudhia
Journal:  Breast Cancer (Dove Med Press)       Date:  2016-10-06

4.  Breast MRI texture analysis for prediction of BRCA-associated genetic risk.

Authors:  Georgia Vasileiou; Maria J Costa; Christopher Long; Iris R Wetzler; Juliane Hoyer; Cornelia Kraus; Bernt Popp; Julius Emons; Marius Wunderle; Evelyn Wenkel; Michael Uder; Matthias W Beckmann; Sebastian M Jud; Peter A Fasching; Alexander Cavallaro; André Reis; Matthias Hammon
Journal:  BMC Med Imaging       Date:  2020-07-29       Impact factor: 1.930

5.  Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Álamo III" retrospective study.

Authors:  Iván Márquez-Rodas; Marina Pollán; María José Escudero; Amparo Ruiz; Miguel Martín; Ana Santaballa; Purificación Martínez Del Prado; Norberto Batista; Raquel Andrés; Antonio Antón; Antonio Llombart; Antonio Fernandez Aramburu; Encarnación Adrover; Sonia González; Miguel Angel Seguí; Lourdes Calvo; José Lizón; Álvaro Rodríguez Lescure; Teresa Ramón Y Cajal; Gemma Llort; Carlos Jara; Eva Carrasco; Sara López-Tarruella
Journal:  PLoS One       Date:  2017-10-06       Impact factor: 3.240

6.  Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis.

Authors:  Haixia Chen; Jianming Wu; Zhihong Zhang; Yong Tang; Xiaoxuan Li; Shuangqing Liu; Shousong Cao; Xianzhu Li
Journal:  Front Pharmacol       Date:  2018-08-21       Impact factor: 5.810

7.  BRCA1/2 mutation spectrum in Chinese early-onset breast cancer.

Authors:  Mengjia Shen; Libo Yang; Ting Lei; Lin Xiao; Li Li; Peichuan Zhang; Weiyi Feng; Feng Ye; Hong Bu
Journal:  Transl Cancer Res       Date:  2019-04       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.